SAGE Therapeutics Inc (SAGE.OQ)
SAGE.OQ on NASDAQ Stock Exchange Global Market
148.01USD
20 Apr 2018
148.01USD
20 Apr 2018
Change (% chg)
$-21.66 (-12.77%)
$-21.66 (-12.77%)
Prev Close
$169.67
$169.67
Open
$168.53
$168.53
Day's High
$168.53
$168.53
Day's Low
$147.25
$147.25
Volume
369,067
369,067
Avg. Vol
230,980
230,980
52-wk High
$195.97
$195.97
52-wk Low
$59.59
$59.59
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- ownership
- filings
- deals
- private equity
- third-party document and information retrieval
- estimates
- fundamentals
- economics
- events
- news
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
Name | Age | Since | Current Position |
---|---|---|---|
Kevin Starr |
54 | 2016 | Independent Chairman of the Board |
Jeffrey Jonas |
64 | 2013 | President, Chief Executive Officer, Director |
Kimi Iguchi |
53 | 2016 | Chief Financial Officer, Treasurer |
Anne Cook |
54 | 2016 | Senior Vice President, General Counsel |
Amy Schacterle |
2017 | Senior Vice President - Regulatory Affairs and Quality Assurance |
- Why Oppenheimer Global fund is focusing on biotech as rates rise
- Why Oppenheimer Global fund is focusing on biotech as rates rise
- Why Oppenheimer Global fund is focusing on biotech as rates rise
- BRIEF-Sage Therapeutics Qtrly Net Loss Per Share $1.75
- BRIEF-Sage Therapeutics Prices Public Offering Of 3.5 Mln Shares At $164/Share